S. Moschos

发表

Genomic Classification of Cutaneous Melanoma

Steven J. M. Jones, Martin L. Miller, Jared C Malke, 2015, Cell.

Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?

V. Gorgoulis, C. Kittas, S. Moschos, 2001, Anticancer research.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Prognostic value of B cells in cutaneous melanoma

Lisle E. Mose, Sara R. Selitsky, K. Hoadley, 2019, Genome Medicine.

Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice.

C. Mantzoros, M. Sleeman, S. Wiegand, 2004, Diabetes.

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials

Olga V. Marchenko, A. Ivanova, O. Marchenko, 2016, Journal of biopharmaceutical statistics.

Monitoring rules for toxicity in Phase II oncology trials

Olga V. Marchenko, A. Ivanova, O. Marchenko, 2015 .

Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes

J. Grilley-Olson, S. Moschos, P. Googe, 2020, The American Journal of dermatopathology.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC

D. Hayes, M. Wilkerson, M. Gulley, 2015, PloS one.

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Leptin in relation to carcinoma In situ of the breast: A study of pre‐menopausal cases and controls

C. Mantzoros, D. Cramer, S. Moschos, 1999, International journal of cancer.

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

M. Atkins, P. Durani, F. Hodi, 2021, The Lancet. Oncology.

Leptin: in search of role(s) in human physiology and pathophysiology

C. Mantzoros, S. Moschos, 1998, Clinical endocrinology.

Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity.

C. Mantzoros, J. Flier, S. Moschos, 2002, Diabetes.

Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

J. Kirkwood, H. Tawbi, S. Moschos, 2009, Nature Clinical Practice Oncology.

Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays

J. Becker, F. Jenkins, P. Moore, 2009, International journal of cancer.

Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents

S. Moschos, 2022, American Journal of Clinical Dermatology.

The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma

M. Gulley, Douglas B. Johnson, R. Alkallas, 2022, BMC Cancer.

Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases

J. Kirkwood, S. Moschos, D. Trembath, 2021, Melanoma research.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients

J. Kirkwood, J. Finke, M. Mandić, 2014, Front. Oncol..

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

R. Sullivan, K. Flaherty, Douglas B. Johnson, 2022, Investigational New Drugs.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-&agr;2b in patients with metastatic melanoma

J. Kirkwood, S. Moschos, C. Sander, 2017, Melanoma research.

In reply [2]

J. Kirkwood, L. Schuchter, S. Moschos, 2005 .

Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience

A. Ivanova, Carrie Lee, S. Moschos, 2019, Oncology.

Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696

J. Kirkwood, L. Butterfield, T. Whiteside, 2009, Clinical Cancer Research.

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

S. Moschos, H. Muss, S. Shachar, 2016, Cancer treatment reviews.

Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans.

C. Mantzoros, J. Flier, N. Katsilambros, 1997, The Journal of clinical endocrinology and metabolism.

Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency.

J. Chan, C. Mantzoros, X. Li, 2005, The Journal of clinical endocrinology and metabolism.

The emerging clinical significance of leptin in humans with absolute or relative leptin deficiency

C. Mantzoros, S. Moschos, 2005 .

Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies.

S. Moschos, A. Salama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Ciliary Neurotrophic FactorAx 15 Alters Energy Homeostasis , Decreases Body Weight , and Improves Metabolic Control in Diet-Induced Obese and UCP 1-DTA Mice

C. Mantzoros, M. Sleeman, S. Wiegand, 2004 .

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

J. Kirkwood, M. Lotze, M. Mandić, 2008, Clinical immunology.

Leptin in Immunology1

C. Mantzoros, G. Matarese, S. Moschos, 2005, The Journal of Immunology.

Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases

L. Carey, E. Brogi, K. Blackwell, 2019, Breast Cancer Research and Treatment.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

C. Miller, David B. Darr, N. Sharpless, 2015, Clinical Cancer Research.

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

R. Sullivan, K. Flaherty, Douglas B. Johnson, 2022, Investigational New Drugs.

Melanoma cells appropriate pericyte:endothelial cell crosstalk during perivascular invasion in the brain

David F. Kashatus, S. Moschos, Pankaj Kumar, 2022, bioRxiv.

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

M. Atkins, F. Hodi, H. Tawbi, 2017 .

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma

J. Kirkwood, S. Moschos, M. Panelli, 2008, Nature Clinical Practice Oncology.

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

Combined modality neoadjuvant treatment for stage III/IV melanoma with PD-1 blockade plus radiation: A case series

L. Dodd, Michail Alevizakos, S. Moschos, 2017 .

Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.

S. Moschos, D. Becker, Xiaolei Wang, 2010, Genes & cancer.

The use of endostatin in the treatment of solid tumors.

M. Karamouzis, S. Moschos, 2009, Expert Opinion on Biological Therapy.

Leptin and reproduction: a review.

J. Chan, C. Mantzoros, S. Moschos, 2002, Fertility and sterility.

The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications

C. Mantzoros, S. Moschos, Stergios J. Moschos, 2002, Oncology.

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

D. Jukic, J. Kirkwood, S. Moschos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma

David L. Marron, D. Hayes, K. Hoadley, 2019, Front. Oncol..

Historical review of melanoma treatment and outcomes.

S. Moschos, D. Ollila, F. Collichio, 2013, Clinics in dermatology.

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

C. J. Thompson, C. Amos, I. Gorlov, 2022, medRxiv.

DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features

K. Conway, S. Edmiston, M. Berwick, 2014, Pigment cell & melanoma research.

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas

D. Jukic, J. Kirkwood, C. Athanassiou, 2007, Oncogene.

Next generation of immunotherapy for melanoma.

J. Kirkwood, H. Zarour, L. Butterfield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Yu Shyr, Fei Ye, Donald Lawrence, 2012, The New England journal of medicine.

The Type I Interferon System With Emphasis on Its Role in Malignancies

J. Kirkwood, G. Lesinski, S. Moschos, 2007 .

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

J. Kirkwood, S. Moschos, A. Tarhini, 2011, British Journal of Cancer.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma

Derek Y. Chiang, J. Parker, N. Sharpless, 2014, Pigment cell & melanoma research.

Targeting Ubc9 for cancer therapy

Y. Mo, S. Moschos, 2005, Expert opinion on therapeutic targets.

Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of POLD1 and MLH1.

D. Hayes, J. Parker, J. Auman, 2017, JCO precision oncology.

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies

S. Moschos, A. Salama, April K. S. Salama, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrins and cancer.

J. Kirkwood, S. Moschos, Shelley L Reppert, 2007, Oncology.

Interferons in the treatment of solid tumors.

J. Kirkwood, S. Moschos, S. Varanasi, 2005, Cancer treatment and research.

Role of SUMO/Ubc9 in DNA Damage Repair and Tumorigenesis

Y. Mo, S. Moschos, 2006, Journal of Molecular Histology.

Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells

J. Kirkwood, M. Lotze, S. Moschos, 2011, Journal of immunotherapy.

HIF 1 a and HIF 2 a independently activate SRC to promote melanoma metastases

Lukas D. Osborne, C. Miller, Kwok-Kin Wong, 2018 .

HIF1α and HIF2α independently activate SRC to promote melanoma metastases.

Lukas D. Osborne, C. Miller, Kwok-Kin Wong, 2013, The Journal of clinical investigation.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

M. Wilkerson, J. Parker, K. Conway, 2019, The Journal of investigative dermatology.

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.

P. Danaher, R. Sullivan, E. Schmidt, 2018 .

Targeted therapies in melanoma.

S. Moschos, Ramya Pinnamaneni, R. Pinnamaneni, 2015, Surgical oncology clinics of North America.

The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy

D. Fried, D. Sasaki-Adams, L. Marks, 2017, Anti-cancer drugs.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

Induction of Gsk3β-β-TrCP Interaction Is Required for Late Phase Stabilization of β-Catenin in Canonical Wnt Signaling*

Xiang Xu, Jing Hu, S. Moschos, 2014, The Journal of Biological Chemistry.

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

J. Kirkwood, H. Tawbi, S. Moschos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

R. White, P. Wen, P. Brastianos, 2016, Pigment cell & melanoma research.

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.

J. Kirkwood, H. Tawbi, M. Egorin, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)

J. Serody, A. Ivanova, E. Dees, 2021, Melanoma research.

Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation

D. Jukic, S. Moschos, D. Becker, 2009, Cancer biology & therapy.

Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues.

D. Jukic, R. Dhir, C. Athanassiou, 2010, Human pathology.

Brain Tumor Microenvironment and Angiogenesis in Melanoma Brain Metastases

J. Kirkwood, B. Vincent, Carrie Lee, 2021, Frontiers in Oncology.

A principal case of multiple lymphoid collision tumors involving both B-cell chronic lymphocytic leukemia and metastatic malignant melanoma.

D. Jukic, S. Moschos, A. Cantor, 2010, Dermatology online journal.

Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans

C. Mantzoros, J. Flier, N. Katsilambros, 1997 .

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

J. Kirkwood, J. Ho, B. Van Houten, 2012, Molecular Cancer.

Mitochondrial Respiration - An Important Therapeutic Target in Melanoma

J. Kirkwood, T. Conrads, B. Van Houten, 2012, PloS one.

Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).

Yibing Yan, S. Theocharis, S. Moschos, 2022, Current problems in cancer.

Brain Metastases from Cutaneous Melanoma

Carrie Lee, M. Ewend, S. Moschos, 2016 .

Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article.

D. Kondziolka, J. Flickinger, L. Lunsford, 2011, Journal of neurosurgery.

Endostatin plus interferon-&agr;2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents

J. Kirkwood, S. Moschos, S. Land, 2007, Melanoma research.

Multiregional genetic evolution of metastatic uveal melanoma

Michael A. Durante, K. Wrzeszczynski, A. Shoushtari, 2021, npj Genomic Medicine.

Multiregional genetic evolution of metastatic uveal melanoma

Michael A. Durante, K. Wrzeszczynski, A. Shoushtari, 2021, NPJ genomic medicine.

Prognostic value of B cells in cutaneous melanoma

Lisle E. Mose, K. Hoadley, J. Parker, 2019, Genome Medicine.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma

J. Kirkwood, S. Moschos, C. Sander, 2012, Journal of immunotherapy.

Responsiveness to peripherally administered melanocortins in lean and obese mice.

C. Mantzoros, S. Moschos, E. Maratos-Flier, 2004, Diabetes.

Pathologic and gene expression features of metastatic melanomas to the brain

D. Kondziolka, J. Kirkwood, M. Romkes, 2013, Cancer.

Strategies for the Development of More Effective Adjuvant Therapy of Melanoma: Current and Future Explorations of Antibodies, Cytokines, Vaccines, and Combinations

J. Kirkwood, S. Moschos, Wenjun Wang, 2006, Clinical Cancer Research.

Adjuvant Therapy for Cutaneous Melanoma

J. Kirkwood, S. Moschos, A. Tarhini, 2011 .

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

J. Kirkwood, J. Ho, S. Moschos, 2012, Molecular Cancer.

Targeted Therapy for Melanoma

S. Moschos, 2011 .

Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.

J. Kirkwood, S. Moschos, 2007, Cytokine & growth factor reviews.

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

J. Kirkwood, S. Moschos, P. Konstantinopoulos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of sequential temozolomide chemotherapy followed by high‐dose interleukin 2 immunotherapy for metastatic melanoma

J. Kirkwood, S. Moschos, W. Gooding, 2008, Cancer.

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma

Mauricio Castillo, Yueh Z. Lee, Yueh Z Lee, 2016, Journal of computer assisted tomography.

A 61 YEAR DIABETIC MAN WITH METHICILLIN‐SENSITIVE STAPHYLOCOCCUS AUREUS SEPTIC ARTHRITIS AND ACUTE RENAL FAILURE: A CASE OF IGA‐DOMINANT POSTINFECTIOUS GLOMERULONEPHRITIS

A. Im, S. Bastacky, S. Moschos, 2012, Nephrology.

The use of endostatin in the treatment of solid tumors

M. Karamouzis, S. Moschos, 2009 .

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

Zhentao Yang, A. Ribas, R. Lo, 2023, Cancer discovery.

Multi-organ landscape of therapy-resistant melanoma

Zhentao Yang, P. Scumpia, Douglas B. Johnson, 2023, Nature Medicine.

Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma

Manuela Buzoianu, Charalambos Athanassiou, Drazen M Jukic, 2010, Journal of immunotherapy.

Abstract 5024: mDX400, the murine analog against the anti-PD1 antibody MK-347 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer

C. Perou, David B. Darr, N. Sharpless, 2014 .

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

Wei Zhao, S. Moschos, P. Googe, 2022, medRxiv.

COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

K. Flaherty, A. Arance, J. Grob, 2017 .

Resolving "kinks" of chemotherapy in melanoma.

J. Kirkwood, P. Chaudhary, S. Moschos, 2008, Journal of the National Cancer Institute.

Development of [18F]F-5-OMe-Tryptophans through Photoredox Radiofluorination: A New Method to Access Tryptophan-Based PET Agents.

Yaofeng Desmond Zhong, S. Moschos, Zhanhong Wu, 2023, Journal of medicinal chemistry.

Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy

R. Sullivan, Melissa L. Johnson, M. Opyrchal, 2019, Clinical Trials.

Interferon therapy.

J. Kirkwood, S. Moschos, 1982, World Health Organization technical report series.

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012 .

Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).

R. Sullivan, E. Rasmussen, Douglas B. Johnson, 2017 .

Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

J. Kirkwood, H. Tawbi, S. Moschos, 2010 .